The researchers analyzed serum antibody levels – the clear part of the blood – from a subset of 30 children in this group one month after their third intake and found that antibodies to the Omicron variant were 36 times higher than they were. after the second dose of the vaccine. In an analysis of 140 children without evidence of prior Covid-19 infection, antibody levels against the original SARS-CoV-2 virus strain were six times higher one month after the booster dose than one month after the second dose. of the vaccine. The companies said there were no safety issues related to the booster dose of the vaccine in these small groups of children. Pfizer and BioNTech say they will ask the FDA for an emergency use license, or EUA, for a booster dose for children in this age group “in the coming days”. Data will also be shared with the European Medicines Agency and other regulatory agencies. Studies by the New York State Department of Health and the U.S. Centers for Disease Control and Prevention found that the effectiveness of the Pfizer vaccine for children ages 5-12 decreased significantly during the Omicron increase, falling from 68% to about 12 % vs. Covid-19. contamination. However, two doses of the vaccine continued to provide protection against more serious illnesses resulting in emergency care or hospitalization. The main series of two doses was approved by the FDA for emergency use in this age group in October. Pfizer booster doses of Cfid-19 vaccine have already been approved for people 12 years of age and older.
